Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy.

Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, Horváth G, Papp M, Palatka K, Nyári T, Bálint A, Lőrinczy K, Wittmann T.

Aliment Pharmacol Ther. 2013 Jan;37(2):225-33. doi: 10.1111/apt.12160. Epub 2012 Nov 26.

2.

Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.

Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, Palatka K, Bálint A, Bor R, Wittmann T, Molnár T.

Scand J Gastroenterol. 2013 Dec;48(12):1394-8. doi: 10.3109/00365521.2013.845906. Epub 2013 Oct 16.

PMID:
24131338
3.

Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T.

J Gastrointestin Liver Dis. 2012 Sep;21(3):265-9.

4.

[Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Kiss T, Wittmann T.

Orv Hetil. 2011 Jun 12;152(24):951-7. doi: 10.1556/OH.2011.29128. Hungarian.

PMID:
21609921
5.

Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.

Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives..

Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22.

PMID:
21945953
6.

Elective switching from infliximab to adalimumab in stable Crohn's disease.

Hoentjen F, Haarhuis BJ, Drenth JP, de Jong DJ.

Inflamm Bowel Dis. 2013 Mar-Apr;19(4):761-6. doi: 10.1097/MIB.0b013e3182802ae1.

PMID:
23446337
7.

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group..

Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24.

8.

Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.

af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.

Scand J Gastroenterol. 2013 May;48(5):543-51. doi: 10.3109/00365521.2013.772230. Epub 2013 Mar 12.

PMID:
23477356
9.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
10.

Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.

Laharie D, Mesli S, El Hajbi F, Chabrun E, Chanteloup E, Capdepont M, Razaire S, de Lédinghen V, Zerbib F.

Aliment Pharmacol Ther. 2011 Aug;34(4):462-9. doi: 10.1111/j.1365-2036.2011.04743.x. Epub 2011 Jun 14.

11.

Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.

Trinder MW, Lawrance IC.

J Gastroenterol Hepatol. 2009 Jul;24(7):1252-7. doi: 10.1111/j.1440-1746.2009.05786.x. Epub 2009 Feb 12.

PMID:
19220669
12.

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

Orlando A, Renna S, Mocciaro F, Cappello M, Di Mitri R, Randazzo C, Cottone M.

Inflamm Bowel Dis. 2012 May;18(5):826-31. doi: 10.1002/ibd.21835. Epub 2011 Aug 11.

PMID:
21837774
13.

Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?

Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA.

Aliment Pharmacol Ther. 2005 Dec;22(11-12):1107-13.

14.

Scheduled maintenance therapy with infliximab improves the prognosis of Crohn's disease: a single center prospective cohort study in Japan.

Takahashi S, Takagi S, Shiga H, Umemura K, Endo K, Kakuta Y, Takahashi S, Kinouchi Y, Shimosegawa T.

Tohoku J Exp Med. 2010 Mar;220(3):207-15.

15.

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB.

Scand J Gastroenterol. 2012 May;47(5):518-27. doi: 10.3109/00365521.2012.660541. Epub 2012 Mar 1.

PMID:
22375898
16.

Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.

Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, Swatton A, Tripoli S, Vaizey CJ, Kamm MA, Phillips R, Hart A.

Inflamm Bowel Dis. 2012 Oct;18(10):1825-34. doi: 10.1002/ibd.21940. Epub 2012 Jan 4.

PMID:
22223472
17.

Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.

Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.

Rev Med Chir Soc Med Nat Iasi. 2010 Jan-Mar;114(1):85-90.

PMID:
20509281
18.

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.

Eur J Gastroenterol Hepatol. 2010 Mar;22(3):334-9. doi: 10.1097/MEG.0b013e32832b20d4.

PMID:
19528808
19.

Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.

Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.

Aliment Pharmacol Ther. 2012 Jun;35(12):1397-407. doi: 10.1111/j.1365-2036.2012.05100.x. Epub 2012 Apr 22.

20.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.

PMID:
17470824

Supplemental Content

Support Center